Last reviewed · How we verify
Tricortin 1000
Tricortin 1000 is a corticotropin (ACTH) analog that stimulates the adrenal cortex to produce endogenous corticosteroids.
Tricortin 1000 is a corticotropin (ACTH) analog that stimulates the adrenal cortex to produce endogenous corticosteroids. Used for Adrenocortical insufficiency, Infantile spasms (West syndrome).
At a glance
| Generic name | Tricortin 1000 |
|---|---|
| Also known as | Tricortin |
| Sponsor | Fidia Farmaceutici s.p.a. |
| Drug class | ACTH analog |
| Target | Melanocortin-2 receptor (MC2R) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Tricortin 1000 is a synthetic analog of adrenocorticotropic hormone (ACTH) that binds to melanocortin-2 receptors on adrenocortical cells, triggering the release of cortisol and other adrenal steroids. This mechanism differs from direct corticosteroid administration by promoting endogenous hormone production rather than exogenous replacement. It is used therapeutically in conditions where stimulation of natural corticosteroid production is beneficial.
Approved indications
- Adrenocortical insufficiency
- Infantile spasms (West syndrome)
Common side effects
- Hypertension
- Hypokalemia
- Hyperglycemia
- Fluid retention
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tricortin 1000 CI brief — competitive landscape report
- Tricortin 1000 updates RSS · CI watch RSS
- Fidia Farmaceutici s.p.a. portfolio CI